Cited by 231RNA Interference and Gene DeliveryRNA and protein synthesis mechanismsMolecular Biology Techniques and Applications

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription

Open access

Henderson, Jordana M., Ujita, Andrew, Hill, Elizabeth, Yousif‐Rosales, Sally, Smith, Cory, Ko, Nicholas, McReynolds, Taylor, Cabral, Charles R., Escamilla‐Powers, Julienne R., Houston, Michael E.·2021·Current Protocols

DOI 10.1002/cpz1.39

Open this paper in CoChat — free account Open PDF

Abstract

Synthetic messenger RNA (mRNA)−based therapeutics are an increasingly popular approach to gene and cell therapies, genome engineering, enzyme replacement therapy, and now, during the global SARS‐CoV‐2 pandemic, vaccine development. mRNA for such purposes can be synthesized through an enzymatic in vitro transcription (IVT) reaction and formulated for in vivo delivery. Mature mRNA requires a 5′‐cap for gene expression and mRNA stability. There are two methods to add a cap in vitro: via a two‐step multi‐enzymatic reaction or co‐transcriptionally. Co‐transcriptional methods minimize reaction steps and enzymes needed to make mRNA when compared to enzymatic capping. CleanCap ® AG co‐transcriptional capping results in 5 mg/ml of IVT with 94% 5′‐cap 1 structure. This is highly efficient compared to first‐generation cap analogs, such as mCap and ARCA, that incorporate cap 0 structures at lower efficiency and reaction yield. This article describes co‐transcriptional capping using TriLink Biotechnology's CleanCap ® AG in IVT. © 2021 The Authors. This article was corrected on 22 November 2021 and 26 July 2022 . See the end of the full text for details. Basic Protocol 1 : IVT with CleanCap Basic Protocol 2 : mRNA purification and analysis

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cpz1.39

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-Cellulose
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,636
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569

Flagged first, then by citations

Show all 38 references

Research works printed but not linked: 1

Green M. R., 2019, Isolation of poly(A)+ messenger RNA using magnetic oligo(dT) beads, Cold Spring Harbor Protocols, 2019

Sorted by citations

Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
Innate immune mechanisms of mRNA vaccines
Verbeke, R., Hogan, M. J., Loré, K., & Pardi, N. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.014 · Cited by 535
Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
Nance, K. D., & Meier, J. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00197 · Cited by 466
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Zhang, L., More, K. R., Ojha, A., Jackson, C. B., Quinlan, B. D., Li, H., He, W., Farzan, M., Pardi, N., & Choe, H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00751-6 · Cited by 244
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 252
mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
Wang, Y., Kumari, M., Chen, G., Hong, M.-H., Yuan, J. P., Tsai, J.-L., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 198
mRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 145
Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications
Leong, K. Y., Tham, S. K., & Poh, C. L. (2025) · Virology Journal · doi:10.1186/s12985-025-02645-6 · Cited by 139
Machine Learning for Designing Next-Generation mRNA Therapeutics
Castillo-Hair, S. M., & Seelig, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00621 · Cited by 122
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124
Current landscape of mRNA technologies and delivery systems for new modality therapeutics
Lu, R., Hsu, H.-E., Perez, S. J. L. P., Kumari, M., Chen, G., Hong, M.-H., Lin, Y.-S., Liu, C.-H., Ko, S.-H., Concio, C. A. P., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01080-z · Cited by 124
The advent of clinical self-amplifying RNA vaccines
Casmil, I. C., Jin, J., Won, E.-J., Huang, C., Liao, S., Cha‐Molstad, H., & Blakney, A. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.060 · Cited by 111
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
Kang, D. D., Li, H., & Dong, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114961 · Cited by 100
Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity
Luozhong, S., Liu, P., Li, R., Yuan, Z., Debley, E. L., Chen, Y., Hu, Y., Cao, Z., Cui, M., McIlhenny, K., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02240-8 · Cited by 106
Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy
Yang, J., Zhu, J., Sun, J., Chen, Y., Du, Y., Tan, Y., Wu, L., Zhai, M., Wei, L., Li, N., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.010 · Cited by 99
Chemical Modifications of mRNA Ends for Therapeutic Applications
Warminski, M., Mamot, A., Depaix, A., Kowalska, J., & Jemielity, J. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00442 · Cited by 91
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 109
Recent progress in mRNA cancer vaccines
Yao, R., Xie, C., & Xia, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2307187 · Cited by 91
Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain
Kis, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020430 · Cited by 84
mRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 85
mRNA Cancer Vaccines: Construction and Boosting Strategies
Liu, X., Huang, P., Yang, R., & Deng, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c05635 · Cited by 79
Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures
Inagaki, M., Abe, N., Li, Z., Nakashima, Y., Acharyya, S., Ogawa, K., Kawaguchi, D., Hiraoka, H., Banno, A., Meng, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38244-8 · Cited by 80
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
Maximizing mRNA vaccine production with Bayesian optimization
Rosa, S. S., Nunes, D., Antunes, L., Prazeres, D. M. F., Marques, M. P. C., & Azevedo, A. M. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28216 · Cited by 70
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 75
mRNA vaccine quality analysis using RNA sequencing
Gunter, H. M., Idrisoglu, S., Singh, S., Han, D. J., Ariens, E., Peters, J. R., Wong, T., Cheetham, S. W., Xu, J., Rai, S. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41354-y · Cited by 69
Harnessing eukaryotic retroelement proteins for transgene insertion into human safe-harbor loci
Zhang, X., Treeck, B. V., Horton, C. A., McIntyre, J. J. R., Palm, S. M., Shumate, J. L., & Collins, K. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02137-y · Cited by 65
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Youssef, M., Hitti, C., Fulber, J. P. C., & Kamen, A. (2023) · Biomolecules · doi:10.3390/biom13101497 · Cited by 63
Understanding the impact of in vitro transcription byproducts and contaminants
Lenk, R., Kleindienst, W., Szabó, G. T., Baiersdörfer, M., Boros, G., Keller, J. M., Mahiny, A. J., & Vlatkovic, I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1426129 · Cited by 63
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization
Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 57
Human RNase 4 improves mRNA sequence characterization by LC–MS/MS
Wolf, E. J., Grünberg, S., Dai, N., Chen, T.-H., Roy, B., Yigit, E., & Junior, I. R. C. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac632 · Cited by 56
Challenges and emerging trends in liquid chromatography-based analyses of mRNA pharmaceuticals
Fekete, S., Doneanu, C. E., Addepalli, B., Gaye, M. M., Nguyen, J. M., Alden, B. A., Birdsall, R. E., Han, D., Isaac, G., & Lauber, M. A. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115174 · Cited by 58
CCND2 Modified mRNA Activates Cell Cycle of Cardiomyocytes in Hearts With Myocardial Infarction in Mice and Pigs
Sun, J., Wang, L., Matthews, R. C., Walcott, G. P., Lu, Y., Wei, Y., Zhou, Y., Zangi, L., & Zhang, J. J. (2023) · Circulation Research · doi:10.1161/circresaha.123.322929 · Cited by 54
An Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 54
Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing
Knipping, F., Newby, G. A., Eide, C. R., McElroy, A. N., Nielsen, S. C., Smith, K. D., Fang, Y., Cornu, T. I., Costa, C., Gutiérrez-Guerrero, A., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.026 · Cited by 53
Characterization of mRNA therapeutics
Guimaraes, G. J., Kim, J., & Bartlett, M. G. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21856 · Cited by 50
Gram‐Scale mRNA Production Using a 250‐mL Single‐Use Bioreactor
Skok, J., Megušar, P., Seravalli, T. V., Pregeljc, D., Mencin, N., Korenč, M., Krušič, A., Celjar, A. M., Pavlin, N., Krušič, J., et al. (2022) · Chemie Ingenieur Technik · doi:10.1002/cite.202200133 · Cited by 44
Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications
Eftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 46
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44
An engineered T7 RNA polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis
Miller, M. G., Alvizo, O., Baskerville, S., Chintala, A., Chng, C., Dassie, J. P., Dorigatti, J. D., Huisman, G. W., Jenne, S., Kadam, S., et al. (2024) · Faraday Discussions · doi:10.1039/d4fd00023d · Cited by 42
Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers
Dietmair, B., Humphries, J., Mercer, T. R., Thurecht, K. J., Howard, C. B., & Cheetham, S. W. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102520 · Cited by 43
Trinucleotide mRNA Cap Analogue N6-Benzylated at the Site of Posttranscriptional m6Am Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo
Warmiński, M., Trepkowska, E., Śmietański, M., Sikorski, P. J., Baranowski, M. R., Bednarczyk, M., Kędzierska, H., Majewski, B., Mamot, A., Papiernik, D., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c12629 · Cited by 43
In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future
Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. V. (2023) · Vaccines · doi:10.3390/vaccines11101600 · Cited by 40
Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases
Vadovics, M., Muramatsu, H., Sárközy, A., & Pardi, N. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_7 · Cited by 40
Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules
Zhang, J., Liu, Y., Li, C., Xiao, Q., Zhang, D., Chen, Y., Rosenecker, J., Ding, X., & Guan, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092182 · Cited by 39
Internal cap-initiated translation for efficient protein production from circular mRNA
Fukuchi, K., Nakashima, Y., Abe, N., Kimura, S., Hashiya, F., Shichino, Y., Liu, Y., Ogisu, R., Sugiyama, S., Kawaguchi, D., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02561-8 · Cited by 42
Quadruple adenine base–edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease–engineered T cells
Engel, N. W., Steinfeld, I., Ryan, D., Anupindi, K., Kim, S., Wellhausen, N., Chen, L., Wilkins, K., Baker, D. J., Rommel, P. C., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2427216122 · Cited by 39
Selective Xi reactivation and alternative methods to restore MECP2 function in Rett syndrome
Grimm, N.-B., & Lee, J. T. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.01.007 · Cited by 34
Complete Chemical Synthesis of Minimal Messenger RNA by Efficient Chemical Capping Reaction
Abe, N., Imaeda, A., Inagaki, M., Li, Z., Kawaguchi, D., Onda, K., Nakashima, Y., Uchida, S., Hashiya, F., Kimura, Y., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00996 · Cited by 35
Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells
Magnani, C. F., Myburgh, R., Brunn, S., Chambovey, M., Ponzo, M., Volta, L. G., Manfredi, F., Pellegrino, C. E., Pascolo, S., Miskey, C., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.07.003 · Cited by 36
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 35
RNase H-based analysis of synthetic mRNA 5′ cap incorporation
Chan, S., Whipple, J. M., Dai, N., Kelley, T. M., Withers, K., Tzertzinis, G., Junior, I. R. C., & Robb, G. B. (2022) · RNA · doi:10.1261/rna.079173.122 · Cited by 32
mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles
McKenzie, R. E., Minnell, J. J., Ganley, M., Painter, G. F., & Draper, S. L. (2023) · Current Protocols · doi:10.1002/cpz1.898 · Cited by 38
Improved mRNA affinity chromatography binding capacity and throughput using an oligo-dT immobilized electrospun polymer nanofiber adsorbent
Dewar, E. A., Guterstam, P., Holland, D. A., Lindman, S., Lundbäck, P., Santos, S. B. D., Wang, S.-C., & Swartz, A. R. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464670 · Cited by 32
State of the Art and Perspectives of Gene Therapy in Heart Failure. A Scientific Statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases
Linthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 29
A synthetic DNA template for fast manufacturing of versatile single epitope mRNA
de Mey, W., Schrijver, P. D., Autaers, D., Pfitzer, L., Fant, B., Locy, H., Esprit, A., Lybaert, L., Bogaert, C., Verdonck, M., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.021 · Cited by 28
mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations
Omidi, Y., Pourseif, M. M., Ansari, R. A., & Barar, J. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2419815 · Cited by 29
Advancing mRNA technologies for therapies and vaccines: An African context
Kairuz, D., Samudh, N., Ely, A., Arbuthnot, P., & Bloom, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018961 · Cited by 25
“The various CleanCap® analogs function by complementary base-pairing to the first two initiating nucleotides following the T7 promoter sequence, a factor that needs to be taken into consideration during initial template design (10, 18).”
Background
Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Wu, Z., Sun, W., & Qi, H. (2024) · Vaccines · doi:10.3390/vaccines12080873 · Cited by 30
The design, manufacture and LNP formulation of mRNA for research use
Leighton, L. J., Chaudhary, N., Tompkins, H. E., Kulkarni, A., Carrodus, N. L., Budzinska, M. A., Das, S. L., Cheetham, S. W., & Mercer, T. R. (2025) · Nature Protocols · doi:10.1038/s41596-025-01174-4 · Cited by 24
Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
Deviatkin, A. A., Simonov, R. A., Trutneva, K. A., Maznina, A. A., Khavina, E. M., & Volchkov, P. (2022) · Vaccines · doi:10.3390/vaccines10050709 · Cited by 26
RNA Therapeutics: A Healthcare Paradigm Shift
Niazi, S. K. (2023) · Biomedicines · doi:10.3390/biomedicines11051275 · Cited by 25
Self-amplifying RNAs generated with the modified nucleotides 5-methylcytidine and 5-methyluridine mediate strong expression and immunogenicity in vivo
Azizi, H., Renner, T. M., Agbayani, G., Simard, B., Dudani, R., Harrison, B. A., Iqbal, U., Jia, Y., McCluskie, M. J., & Akache, B. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae004 · Cited by 28
RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
de Mey, W., Esprit, A., Thielemans, K., Breckpot, K., & Franceschini, L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3304 · Cited by 27
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Rubio‐Casillas, A., Cowley, D., Raszek, M., Uversky, V. N., & Redwan, E. M. M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131427 · Cited by 27
Emerging Progress of RNA-Based Antitumor Therapeutics
Fu, J., Dong, H., Wu, J., & Jin, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83732 · Cited by 23
Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice
Hendricks, G. G., Grigoryan, L., Navarro, M. J., Catanzaro, N., Hubbard, M. L., Powers, J. M., Mattocks, M. D., Treichel, C., Walls, A. C., Lee, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2085 · Cited by 24
Vaccines against COVID-19: Priority to mRNA-Based Formulations
Pascolo, S. (2021) · Cells · doi:10.3390/cells10102716 · Cited by 23
Modified mRNA Therapeutics for Heart Diseases
Magadum, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415514 · Cited by 23
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
Biochemical characterization of mRNA capping enzyme from Faustovirus
Chan, S., Molé, C. N., Nye, D. B., Mitchell, L., Dai, N., Buss, J., Kneller, D. W., Whipple, J. M., & Robb, G. B. (2023) · RNA · doi:10.1261/rna.079738.123 · Cited by 23
CleanCap M6 inhibits decapping of exogenously delivered IVT mRNA
Mandell, Z. F., Ujita, A., Henderson, J. M., Truong, A., Vo, C., Rezvani, F., Abolhassani, N., Lebedev, A. V., Xu, C., Koukhareva, I., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102456 · Cited by 21
Self-citation
mRNA vaccines: immunogenicity and quality characteristics
Quan, Y., Yang, H., Li, W., & Li, L. X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03800-5 · Cited by 27
Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles
Higuchi, A., Sung, T., Wang, T., Ling, Q., Kumar, S. S., Hsu, S.-T., & Umezawa, A. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2106490 · Cited by 21
mRNA Vaccine Platform: mRNA Production and Delivery
Litvinova, V. R., Рудометов, А. П., Карпенко, Л. И., & Ilyichev, A. A. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020152 · Cited by 26
Comprehensive evaluation of T7 promoter for enhanced yield and quality in mRNA production
Sari, Y., Rosa, S. S., Jeffries, J. W. E., & Marques, M. P. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-59978-5 · Cited by 24
Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity
Amano, T., Yu, H., Amano, M., Leyder, E. C., Badiola, M., Ray, P., Kim, J., Ko, A. C., Achour, A., Weng, N., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106335 · Cited by 20
Quantification of mRNA cap-modifications by means of LC-QqQ-MS
Muthmann, N., Špaček, P., Reichert, D., van Dülmen, M., & Rentmeister, A. (2021) · Methods · doi:10.1016/j.ymeth.2021.05.018 · Cited by 19
Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation
Kitte, R., Serfling, R., Blache, U., Seitz, C., Schrader, S., Koehl, U., Fricke, S., Bär, C., & Tretbar, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030965 · Cited by 18
Low Resource Integrated Platform for Production and Analysis of Capped mRNA
Nwokeoji, A. O., Chou, T.-C., & Nwokeoji, E. A. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00609 · Cited by 18
Supercoiled DNA percentage: A key in-process control of linear DNA template for mRNA drug substance manufacturing
Piao, X., Tang, Y., Li, X., Zhang, W., Yang, W., Xu, X., Wang, W., Jiang, J., Xu, J., Hu, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102223 · Cited by 17
Structure and biochemistry-guided engineering of an all-RNA system for DNA insertion with R2 retrotransposons
Edmonds, K. K., Wilkinson, M. E., Strebinger, D., Chen, H., Lash, B., Schaefer, C. C., Zhu, S., Liu, D., Zilberzwige‐Tal, S., Ladha, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61321-z · Cited by 17
mRNA vaccine development and applications: A special focus on tumors (Review)
Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., et al. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5669 · Cited by 17
Maximizing the mRNA productivity for in vitro transcription by optimization of fed-batch strategy
Guo, L., Liu, Z., Song, S., Wang, Y., Yang, M., & Chen, G. (2024) · Biochemical Engineering Journal · doi:10.1016/j.bej.2024.109412 · Cited by 15
Making the Next Generation of Therapeutics: mRNA Meets Synthetic Biology
Hınçer, A., Ahan, R. E., Aras, E., & Şeker, U. Ö. Ş. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00253 · Cited by 15
Non-viral vectors for chimeric antigen receptor immunotherapy
Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15
Rapid and high recovery isolation of mRNA from in vitro transcription system by ammonium sulphate precipitation at room temperature
Feng, X., Li, Z., Su, Z. G., Che, S., Dai, B., Cheng, Y., & Zhang, S. (2024) · Separation and Purification Technology · doi:10.1016/j.seppur.2024.126331 · Cited by 13
Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo
Mamaghani, S., Penna, R. R., Frei, J., Wyss, C., Mellett, M., Look, T., Weiß, T., Guenova, E., Kündig, T. M., Läuchli, S., et al. (2024) · Cells · doi:10.3390/cells13151242 · Cited by 14
Novel Mobile Phase to Control Charge States and Metal Adducts in the LC/MS for mRNA Characterization Assays
Strezsak, S. R., Pimentel, A. J., Hill, I. T., Beuning, P. J., & Skizim, N. J. (2022) · ACS Omega · doi:10.1021/acsomega.2c00185 · Cited by 13
Process and analytical strategies for the safe production of mRNA vaccines and therapeutics
Nowak, C. J. A., Liu, S., Falconer, R. J., & Gerstweiler, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11455-0 · Cited by 16
Affordable mRNA Novel Proteins, Recombinant Protein Conversions, and Biosimilars—Advice to Developers and Regulatory Agencies
Niazi, S. K. (2025) · Biomedicines · doi:10.3390/biomedicines13010097 · Cited by 12
The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize
Janowski, M., & Andrzejewska, A. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.003 · Cited by 12
Research progress of mRNA vaccines for infectious diseases
Zhang, Z., Du, J., Zhang, D., Han, R., Wu, X., & Liang, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03060-x · Cited by 19
Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors
Wang, S., Xu, X., Viitala, T., Shu, Y., & Zhang, H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102737 · Cited by 14

Authors: Henderson, J. M., Ujita, A., Hill, E., Yousif‐Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla‐Powers, J. R., & Houston, M. E.
Affiliations: TriLink BioTechnologies (United States) (US)
Corresponding author: Henderson, Jordana M.
ORCID: Henderson, Jordana M.
Hill, Elizabeth
Venue: Current Protocols
Publisher: Wiley
Published: 2021-02
Volume: 1
Issue: 2
Pages: e39-e39
ISSN: 2691-1299 (ISSN-L)
DOI: 10.1002/cpz1.39
OpenAlex: W3127832258
Cited by: 231
References: 38
Citations by year: 2026: 39 · 2025: 53 · 2024: 49 · 2023: 45 · 2022: 36 · 2021: 9
FWCI: 10.90
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Current Protocols (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Molecular Biology Techniques and Applications
Keywords: mRNA therapeutics, in vitro transcription, mRNA synthesis, mRNA purification, mRNA stability, mRNA vaccines, SARS-CoV-2
MeSH terms: Humans, RNA Cap Analogs, RNA, Messenger, Protein Biosynthesis, RNA Stability, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks